Journal: Japanese journal of clinical oncology
This paper evaluates whether the overall survival benefit seen with the ARASENS triplet regimen (androgen-deprivation therapy + docetaxel + darolutamide) in metastatic castration‑sensitive prostate cancer is simply additive or truly greater than expected from independent drug effects.
Using a mathematical model of independent drug action and published data from ARASENS (triplet) and ARANOTE (doublet without docetaxel), the authors:
- – Reconstructed individual patient survival data and generated a predicted overall survival (OS) curve for a purely additive effect.
- – Compared this predicted curve with the observed OS from the triplet regimen via Cox modeling.
- – Also analyzed time to initial subsequent anticancer therapy to minimize confounding from post‑protocol treatments.
Key findings:
- – Observed OS with the triplet was statistically better than the model‑predicted OS for an additive effect (HR 0.82, 95% CI 0.68–0.99; P = .047), implying ~18% greater benefit than expected from simple additivity.
- – Time to first subsequent anticancer therapy showed an even larger greater‑than‑additive advantage (HR 0.57, 95% CI 0.44–0.74; P < .001), supporting an early, upfront synergy-like effect.
Clinical implication:
The data support using the triplet regimen upfront in metastatic castration‑sensitive prostate cancer, as its benefit appears to exceed what would be expected from merely adding the individual drug effects together.